CONSIDERATIONS TO KNOW ABOUT TRASTUZUMAB HOW DOES IT WORK

One of the more underneath-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) noted that the loss of PTEN was noticed in 36% of HER2-constructive Main breast tumor specimens from clients with phase IV illness. Also, Additionally they confirmed that sufferers with PTEN-deficient tumors experienced